Abstract
In a prospective observational study of 54 patients with human immunodeficiency virus-associated cryptococcal meningitis, the early fungicidal activity of amphotericin B (1 mg/kg/day) was significantly greater than that of fluconazole (400 mg/day). Compared with antiretroviral therapy-naive patients, patients developing cryptococcal meningitis while already receiving antiretroviral therapy had lower baseline fungal burdens and a longer median duration of survival, but there were no differences observed in fungal clearance, cerebrospinal fluid proinflammatory cytokines, or 10-week mortality.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy*
-
AIDS-Related Opportunistic Infections / mortality
-
Adult
-
Amphotericin B / therapeutic use*
-
Anti-Retroviral Agents / adverse effects
-
Anti-Retroviral Agents / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Fluconazole / therapeutic use*
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
Humans
-
Male
-
Meningitis, Cryptococcal / drug therapy*
-
Meningitis, Cryptococcal / mortality
-
Middle Aged
-
Treatment Outcome
Substances
-
Anti-Retroviral Agents
-
Amphotericin B
-
Fluconazole